60 results
6-K
EX-99.1
BYSI
BeyondSpring Inc
19 Aug 20
BeyondSpring Appoints Forty Seven, Inc., Co-Founder and Stanford Hematology Veteran, Dr. Ravindra Majeti, to Board of Directors
6:43am
), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has … my values of enhancing the practice of medicine and improving the care of patients with cancer,” said Dr. Majeti. “BeyondSpring is an innovative
6-K
EX-99.1
BYSI
BeyondSpring Inc
10 Nov 21
BeyondSpring Appoints Commercial Leader Mark Santos to its Board of Directors
4:05pm
Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a clinical stage biopharmaceutical company focused on the development of innovative cancer … in developing a multi-layered approach that drove innovative value for ION’s pharmaceutical partners and physician members, and helped transform and optimize
6-K
EX-99.1
BYSI
BeyondSpring Inc
10 Jan 24
Current report (foreign)
3:00pm
platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced … innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company is advancing its first-in-class lead asset
6-K
EX-99.1
BYSI
BeyondSpring Inc
4 Oct 23
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
4:00pm
for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced … : BYSI) is a global clinical-stage biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for patients
6-K
EX-99.1
BYSI
BeyondSpring Inc
18 Dec 23
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
4:31pm
for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced … : BYSI) is a global clinical-stage biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for patients
6-K
EX-99.1
3wvfa3xadsp3u65l
30 Oct 23
Current report (foreign)
8:05am
6-K
EX-99.1
xdszyo4es3ovnff59
11 Mar 20
BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections Including COVID-19
4:01pm
6-K
EX-99.1
v63uzbxtjweg7nka5qe
26 Feb 24
Current report (foreign)
8:01am
6-K
EX-99.1
frxm u9c40
1 Aug 18
BeyondSpring Appoints Richard J. Daly as Chief Operating Officer to Lead the Transition to Commercialization
7:14am
6-K
EX-99.1
cfy1sl
11 Jan 22
BeyondSpring Announces Organizational Streamlining
4:50pm
6-K
EX-99.1
883xj763 rac6
15 Jun 20
Current report (foreign)
4:39pm
6-K
EX-99.1
0z8dx9470pijhi3pecu
22 Sep 20
BeyondSpring Appoints Elizabeth Czerepak as Chief Financial Officer
5:22pm
6-K
EX-99.1
qppkriskmuk 97
23 Jan 20
BeyondSpring Appoints Pharma Veterans Drs. Daniel Zabrowski and Ramon Mohanlal to Company’s Board of Directors
8:00am
6-K
EX-99.1
8pj9lbdm
23 Nov 22
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
4:30pm
6-K
EX-99.1
orp5f oyqo
18 Dec 20
BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors
6:01am
6-K
EX-99.2
nkn8 qr5w63rmt
23 Oct 18
Current report (foreign)
9:17am
6-K
EX-99.1
fs7fqg5px
1 Apr 21
Current report (foreign)
8:22am
6-K
EX-99.1
ntj04t8
23 Oct 18
Current report (foreign)
9:17am
6-K
EX-99.1
i898mj1my2zwik
16 Nov 20
Current report (foreign)
7:22am
6-K
EX-99.1
zgqjh
3 Sep 20
BeyondSpring Provides Second-Quarter 2020 Financial Results and Business Updates
8:00am